Day One Biopharmaceuticals, Inc. (DAWN) has 20 tenedores institucionales e internos conocidos registrados. El mayor tenedor es Blavatnik Len con 10,684,638 acciones. Otros tenedores destacados incluyen Canaan XI L.P. y TAKEDA PHARMACEUTICAL CO LTD.
En los últimos 12 meses, los internos han realizado 43 transacciones en DAWN acciones — 14 compras (valoradas en RSU Award) y 13 ventas (valoradas en $839.84K). Las compras internas han superado las ventas durante este período, lo que puede señalar confianza en las perspectivas de la empresa.
DAWN Participación de Insiders
Principal Titular
Blavatnik Len
10,684,638 acciones
Compras (12 meses)
14
$0.00 valor
Ventas (12 meses)
13
$839.84K valor
Actividad de Transacciones (12 meses)
Principales Titulares Internos
| # |
Nombre |
Cargo |
Acciones en Propiedad |
Última Declaración |
Tamaño Relativo |
| 1 |
Blavatnik Len |
Director |
10,684,638 |
2022-06-21 |
|
| 2 |
Canaan Xi L.p. |
10 Percent Owner |
6,964,301 |
2022-09-22 |
|
| 3 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
6,230,462 |
2021-12-09 |
|
| 4 |
Atlas Venture Fund Xi, L.p. |
Director |
6,008,534 |
2022-12-14 |
|
| 5 |
Blackman Samuel C. |
Head of R&d |
1,034,015 |
2024-12-12 |
|
| 6 |
Ai Day1 Llc |
10 Percent Owner |
827,586 |
2024-08-05 |
|
| 7 |
Atlas Venture Opportunity Fund I, L.p. |
Director |
793,116 |
2022-07-06 |
|
| 8 |
Atlas Venture Opportunity Fund Ii, L.p. |
10 Percent Owner |
766,667 |
2022-06-22 |
|
| 9 |
Atlas Venture Associates Opportunity I, Llc |
Director |
766,667 |
2022-06-22 |
|
| 10 |
Grant Papanek Julie |
Director |
439,358 |
2022-09-15 |
|
| 11 |
Grant Julie Papanek |
Director |
330,000 |
2023-03-03 |
|
| 12 |
Becker Daniel J. |
Director |
37,500 |
2023-06-26 |
|
| 13 |
Gladstone Michael |
Director |
32,335 |
2024-05-28 |
|
| 14 |
Merendino Lauren |
Chief Commercial Officer |
18,978 |
2026-02-18 |
|
| 15 |
Garland J. Scott |
Director |
15,000 |
2025-06-04 |
|
| 16 |
Nicholson Garry A |
Director |
15,000 |
2025-06-04 |
|
| 17 |
Holles Natalie C. |
Director |
15,000 |
2025-06-04 |
|
| 18 |
Grossman William |
Director |
15,000 |
2025-06-04 |
|
| 19 |
Ramasastry Saira |
Director |
15,000 |
2025-06-04 |
|
| 20 |
Dable Habib J |
Director |
15,000 |
2025-06-04 |
|
Transacciones Recientes (últimos 12 meses)
| Fecha |
Nombre |
Cargo |
Tipo |
Acciones |
Precio |
Valor |
| 2026-02-17 |
Bender Jeremy |
Chief Executive Officer |
Venta Informativa |
15,459 |
$11.60 |
$179.34K |
| 2026-02-15 |
Bender Jeremy |
Chief Executive Officer |
Ejercicio de Opciones (Venta) |
4,750 |
- |
- |
| 2026-02-17 |
Merendino Lauren |
Chief Commercial Officer |
Venta Informativa |
5,814 |
$11.60 |
$67.45K |
| 2026-02-15 |
Merendino Lauren |
Chief Commercial Officer |
Ejercicio de Opciones (Venta) |
3,162 |
- |
- |
| 2026-02-17 |
Dubow Adam |
Gen Counsel & Secretary |
Venta Informativa |
6,395 |
$11.60 |
$74.19K |
| 2026-02-15 |
Dubow Adam |
Gen Counsel & Secretary |
Ejercicio de Opciones (Venta) |
1,750 |
- |
- |
| 2026-02-17 |
Vasconcelles Michael |
Head of Research and Dev. |
Venta Informativa |
2,728 |
$11.60 |
$31.65K |
| 2026-02-15 |
Vasconcelles Michael |
Head of Research and Dev. |
Ejercicio de Opciones |
7,125 |
- |
- |
| 2026-02-17 |
York Charles N Ii |
COO and CFO |
Venta Informativa |
6,065 |
$11.60 |
$70.36K |
| 2026-02-15 |
York Charles N Ii |
COO and CFO |
Ejercicio de Opciones (Venta) |
2,250 |
- |
- |
| 2026-01-30 |
Bender Jeremy |
Chief Executive Officer |
Concesión de RSU |
237,000 |
- |
- |
| 2026-01-30 |
Merendino Lauren |
Chief Commercial Officer |
Concesión de RSU |
74,000 |
- |
- |
| 2026-01-30 |
Dubow Adam |
Gen Counsel & Secretary |
Concesión de RSU |
70,000 |
- |
- |
| 2026-01-30 |
Vasconcelles Michael |
Head of Research and Dev. |
Concesión de RSU |
114,000 |
- |
- |
| 2026-01-30 |
York Charles N Ii |
COO and CFO |
Concesión de RSU |
126,000 |
- |
- |
| 2025-11-25 |
Bender Jeremy |
Chief Executive Officer |
Donación (Otorgada) |
7,225 |
- |
- |
| 2025-11-17 |
Bender Jeremy |
Chief Executive Officer |
Venta Informativa |
15,894 |
$8.91 |
$141.69K |
| 2025-11-15 |
Bender Jeremy |
Chief Executive Officer |
Ejercicio de Opciones (Venta) |
3,570 |
- |
- |
| 2025-11-17 |
Merendino Lauren |
Chief Commercial Officer |
Venta Informativa |
3,726 |
$8.91 |
$33.22K |
| 2025-11-15 |
Merendino Lauren |
Chief Commercial Officer |
Ejercicio de Opciones (Venta) |
3,162 |
- |
- |
| 2025-11-17 |
Dubow Adam |
Gen Counsel & Secretary |
Venta Informativa |
4,319 |
$8.91 |
$38.5K |
| 2025-11-15 |
Dubow Adam |
Gen Counsel & Secretary |
Ejercicio de Opciones (Venta) |
1,750 |
- |
- |
| 2025-11-17 |
York Charles N Ii |
COO and CFO |
Venta Informativa |
4,062 |
$8.91 |
$36.21K |
| 2025-11-15 |
York Charles N Ii |
COO and CFO |
Ejercicio de Opciones (Venta) |
1,375 |
- |
- |
| 2025-11-06 |
Bender Jeremy |
Chief Executive Officer |
Devolución de Acciones |
286,000 |
$11.87 |
$3.39M |
